[Malondialdehyde and reduced glutathione increase in patients with chronic stable ischaemic cardiopathy]

Med Clin (Barc). 2005 Mar 19;124(10):371-3. doi: 10.1157/13072573.
[Article in Spanish]

Abstract

Background and objective: Cardiovascular diseases are associated with the ischemia/reperfusion phenomena and therefore to the oxidation/antioxidation balance. The aim of this study was to determine malondialdehyde, nitric oxide, glutathione, ascorbic and dehydroascorbic acid in patients with chronic ischemic heart disease.

Patients and method: 32 male patients, with chronic ischemic heart disease, between 40 and 60 years of age were studied. These individuals were divided in two groups: 16 with hypertension and 16 without hypertension. Both groups were compared with 31 healthy male subjects (control group).

Results: Significant differences (p < 0.001) was observed in malondialdehyde between no-hypertension ischemic group: 5.3 (1.5) microM and the hypertension ischemic group: 4.8 (1.3) microM in contrast with the healthy group: 2.2 (0.5) microM. Hypertension ischemic group showed significant greater reduced glutation levels: 286.1 (31.4) microg/ml than control group 262.0 (38.8) microg/ml; p < 0.03 and no-hypertension ischemic group: 256.4 (41.5) microg/ml; p < 0.02. No significant difference in the rest of the parameters for all study groups.

Conclusions: Oxidation/antioxidation balance during chronic ischemic heart disease can be considered as a good metabolic ischemia indicator, that used in the monitoring and therapeutic evaluation could detect molecular changes that anticipate installation of tissue damage.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adult
  • Chronic Disease
  • Electrocardiography
  • Glutathione / blood
  • Glutathione / metabolism*
  • Humans
  • Male
  • Malondialdehyde / blood
  • Malondialdehyde / metabolism*
  • Middle Aged
  • Myocardial Ischemia / blood
  • Myocardial Ischemia / metabolism*

Substances

  • Malondialdehyde
  • Glutathione